These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20942747)

  • 1. Targeting oxidative stress in cancer.
    Lawless MW; O'Byrne KJ; Gray SG
    Expert Opin Ther Targets; 2010 Nov; 14(11):1225-45. PubMed ID: 20942747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Histone acetylation, gene regulation and depression].
    Vialou V
    Med Sci (Paris); 2010 May; 26(5):465-7. PubMed ID: 20510142
    [No Abstract]   [Full Text] [Related]  

  • 3. Curcumin-induced histone hypoacetylation: the role of reactive oxygen species.
    Kang J; Chen J; Shi Y; Jia J; Zhang Y
    Biochem Pharmacol; 2005 Apr; 69(8):1205-13. PubMed ID: 15794941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors.
    Marks PA; Richon VM; Miller T; Kelly WK
    Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylases and cancer: causes and therapies.
    Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK
    Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone acetylation in gene regulation.
    Verdone L; Agricola E; Caserta M; Di Mauro E
    Brief Funct Genomic Proteomic; 2006 Sep; 5(3):209-21. PubMed ID: 16877467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone modification enzymes: novel targets for cancer drugs.
    Kristeleit R; Stimson L; Workman P; Aherne W
    Expert Opin Emerg Drugs; 2004 May; 9(1):135-54. PubMed ID: 15155140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone post-translational modification: from discovery to the clinic.
    Thomas NR
    IDrugs; 2006 Jun; 9(6):398-401. PubMed ID: 16752306
    [No Abstract]   [Full Text] [Related]  

  • 9. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
    Mai A; Altucci L
    Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
    Epping MT; Bernards R
    Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biological diversity of protein lysine acetylation which has been revealed by small molecule inhibitors].
    Shimazu T; Horinouchi S; Yoshida M
    Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1751-7. PubMed ID: 18051411
    [No Abstract]   [Full Text] [Related]  

  • 13. Potential of histone deacetylase inhibitors for bladder cancer treatment.
    Tanji N; Ozawa A; Kikugawa T; Miura N; Sasaki T; Azuma K; Yokoyama M
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):959-65. PubMed ID: 21707293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone acetyl transferases as emerging drug targets.
    Dekker FJ; Haisma HJ
    Drug Discov Today; 2009 Oct; 14(19-20):942-8. PubMed ID: 19577000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule modulators in epigenetics: implications in gene expression and therapeutics.
    Swaminathan V; Reddy BA; Ruthrotha Selvi B; Sukanya MS; Kundu TK
    Subcell Biochem; 2007; 41():397-428. PubMed ID: 17484138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of cardiac growth by histone acetylation/deacetylation.
    Backs J; Olson EN
    Circ Res; 2006 Jan; 98(1):15-24. PubMed ID: 16397154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.
    Bush EW; McKinsey TA
    Circ Res; 2010 Feb; 106(2):272-84. PubMed ID: 20133912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
    Yoshida M; Shimazu T; Matsuyama A
    Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass spectrometry in epigenetic research.
    Beck HC
    Methods Mol Biol; 2010; 593():263-82. PubMed ID: 19957154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.